{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:29:13Z","timestamp":1784863753690,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T00:00:00Z","timestamp":1650067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T00:00:00Z","timestamp":1650067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"PharmaEssentia Japan K.K."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s12185-022-03341-9","type":"journal-article","created":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T20:03:02Z","timestamp":1650139382000},"page":"215-227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study"],"prefix":"10.1007","volume":"116","author":[{"given":"Yoko","family":"Edahiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohshi","family":"Ohishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Gotoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuto","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohiko","family":"Shibayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Usuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"VanWart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleh","family":"Zagrijtschuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kawase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narihisa","family":"Miyachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Kirito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,16]]},"reference":[{"key":"3341_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2147\/TCRM.S213020","volume":"17","author":"G Benevolo","year":"2021","unstructured":"Benevolo G, Vassallo F, Urbino I, Giai V. Polycythemia Vera (PV): update on emerging treatment options. Ther Clin Risk Manag. 2021;17:209\u201321.","journal-title":"Ther Clin Risk Manag"},{"key":"3341_CR2","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo S, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779\u201390.","journal-title":"N Engl J Med"},{"key":"3341_CR3","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1038\/s41375-018-0349-9","volume":"33","author":"JS Fowles","year":"2019","unstructured":"Fowles JS, How J, Allen MJ, Oh ST. Young versus old age at diagnosis confers distinct genomic profiles in patients with polycythemia vera. Leukemia. 2019;33:1522\u20136.","journal-title":"Leukemia"},{"key":"3341_CR4","doi-asserted-by":"publisher","first-page":"3953","DOI":"10.1200\/JCO.2015.61.6474","volume":"33","author":"BL Stein","year":"2015","unstructured":"Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK, et al. Polycythemia Vera: an appraisal of the biology and management 10 years after the discovery of JAK2 V617F. J Clin Oncol. 2015;33:3953\u201360.","journal-title":"J Clin Oncol"},{"key":"3341_CR5","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00277-015-2357-4","volume":"94","author":"M Griesshammer","year":"2015","unstructured":"Griesshammer M, Gisslinger H, Mesa R. Current and future treatment options for polycythemia vera. Ann Hematol. 2015;94:901\u201310.","journal-title":"Ann Hematol"},{"key":"3341_CR6","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27:1874\u201381.","journal-title":"Leukemia"},{"key":"3341_CR7","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1532\/IJH97.06009","volume":"83","author":"K Dan","year":"2006","unstructured":"Dan K, Yamada T, Kimura Y, Usui N, Okamoto S, Sugihara T, et al. Clinical features of polycythemia vera and essential thrombocythemia in Japan: retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group. Int J Hematol. 2006;83:443\u20139.","journal-title":"Int J Hematol"},{"key":"3341_CR8","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s12185-018-2428-0","volume":"107","author":"A Kamiunten","year":"2018","unstructured":"Kamiunten A, Shide K, Kameda T, Sekine M, Kubuki Y, Ito M, et al. Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan. Int J Hematol. 2018;107:681\u20138.","journal-title":"Int J Hematol"},{"key":"3341_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","volume":"8","author":"T Barbui","year":"2018","unstructured":"Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8:15.","journal-title":"Blood Cancer J"},{"key":"3341_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/bjh.12117","volume":"160","author":"G Bonicelli","year":"2013","unstructured":"Bonicelli G, Abdulkarim K, Mounier M, Johansson P, Rossi C, Jooste V, et al. Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients. Br J Haematol. 2013;160:251\u20134.","journal-title":"Br J Haematol"},{"key":"3341_CR11","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.3109\/10428194.2012.759656","volume":"54","author":"BL Stein","year":"2013","unstructured":"Stein BL, Saraf S, Sobol U, Halpern A, Shammo J, Rondelli D, et al. Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. Leuk Lymphoma. 2013;54:1989\u201395.","journal-title":"Leuk Lymphoma"},{"key":"3341_CR12","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","volume":"32","author":"T Barbui","year":"2018","unstructured":"Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057\u201369.","journal-title":"Leukemia"},{"key":"3341_CR13","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in Oncology: Myeloproliferative neoplasms. Version 2. 2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mpn.pdf. Accessed 15 Dec 2021."},{"issue":"Suppl 5","key":"3341_CR14","doi-asserted-by":"publisher","first-page":"v85","DOI":"10.1093\/annonc\/mdv203","volume":"26","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Barbui T, Cervantes F, Harrison C, Kiladjian JJ, Kr\u00f6ger N, et al. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v85-99.","journal-title":"Ann Oncol"},{"key":"3341_CR15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/bjh.15648","volume":"184","author":"MF McMullin","year":"2019","unstructured":"McMullin MF, Harrison CN, Ali S, Cargo C, Chen F, Ewing J, et al. A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline. Br J Haematol. 2019;184:176\u201391.","journal-title":"Br J Haematol."},{"key":"3341_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3904\/kjim.2020.319","volume":"36","author":"SY Kim","year":"2021","unstructured":"Kim SY, Bae SH, Bang SM, Eom KS, Hong J, Jang S, et al. The 2020 revision of the guidelines for the management of myeloproliferative neoplasms. Korean J Intern Med. 2021;36:45\u201362.","journal-title":"Korean J Intern Med"},{"key":"3341_CR17","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.mayocp.2015.05.014","volume":"90","author":"A Tefferi","year":"2015","unstructured":"Tefferi A, Barbui T. Essential thrombocythemia and polycythemia vera: focus on clinical practice. Mayo Clin Proc. 2015;90:1283\u201393.","journal-title":"Mayo Clin Proc"},{"key":"3341_CR18","doi-asserted-by":"crossref","unstructured":"Shimoda K, Takahashi N, Kirito K, Iriyama N, Kawaguchi T, Kizaki M. JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)\/myeloproliferative neoplasms (MPN). Int J Hematol. 2020; 112:268\u2013291.","DOI":"10.1007\/s12185-020-02964-0"},{"key":"3341_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41408-017-0042-7","volume":"8","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera treatment algorithm 2018. Blood Cancer J. 2018;8:3.","journal-title":"Blood Cancer J"},{"key":"3341_CR20","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","volume":"105","author":"G Finazzi","year":"2005","unstructured":"Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005;105:2664\u201370.","journal-title":"Blood"},{"key":"3341_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00282-997-0011-x","volume":"39","author":"E Liozon","year":"1997","unstructured":"Liozon E, Brigaudeau C, Trimoreau F, Desangles F, Fermeaux V, Praloran V, et al. Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature. Hematol Cell Ther. 1997;39:11\u20138.","journal-title":"Hematol Cell Ther"},{"key":"3341_CR22","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1182\/bloodadvances.2019000655","volume":"3","author":"J Hong","year":"2019","unstructured":"Hong J, Lee JH, Byun JM, Lee JY, Koh Y, Shin DY, et al. Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms. Blood Adv. 2019;3:3700\u20138.","journal-title":"Blood Adv"},{"key":"3341_CR23","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1080\/10428194.2019.1688323","volume":"61","author":"D Tremblay","year":"2020","unstructured":"Tremblay D, King A, Li L, Moshier E, Coltoff A, Koshy A, et al. Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis. Leuk Lymphoma. 2020;61:660\u20137.","journal-title":"Leuk Lymphoma"},{"key":"3341_CR24","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1007\/s00277-021-04647-0","volume":"100","author":"R Sekhri","year":"2021","unstructured":"Sekhri R, Sadjadian P, Becker T, Kolatzki V, Huenerbein K, Meixner R, et al. Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies. Ann Hematol. 2021;100:2707\u201316.","journal-title":"Ann Hematol"},{"key":"3341_CR25","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jfma.2020.09.018","volume":"120","author":"SJ Hsu","year":"2021","unstructured":"Hsu SJ, Yu ML, Su CW, Peng CY, Chien RN, Lin HH, et al. Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C. J Formos Med Assoc. 2021;120:956\u201364.","journal-title":"J Formos Med Assoc"},{"key":"3341_CR26","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s12079-018-0492-0","volume":"13","author":"V Gupta","year":"2019","unstructured":"Gupta V, Bhavanasi S, Quadir M, Singh K, Ghosh G, Vasamreddy K, et al. Protein PEGylation for cancer therapy: bench to bedside. J Cell Commun Signal. 2019;13:319\u201330.","journal-title":"J Cell Commun Signal"},{"key":"3341_CR27","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/ajh.23928","volume":"90","author":"NC Them","year":"2015","unstructured":"Them NC, Bagienski K, Berg T, Gisslinger B, Schalling M, Chen D, et al. Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. Am J Hematol. 2015;90:288\u201394.","journal-title":"Am J Hematol"},{"key":"3341_CR28","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","volume":"126","author":"H Gisslinger","year":"2015","unstructured":"Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, et al. Ropeginterferon alfa-2b, a novel IFN\u03b1-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015;126:1762\u20139.","journal-title":"Blood"},{"issue":"Supplement 1","key":"3341_CR29","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1182\/blood-2018-99-118584","volume":"132","author":"H Gisslinger","year":"2018","unstructured":"Gisslinger H, Buxhofer-Ausch V, Thaler J, Forjan E, Willenbacher E, Wolf D, et al. Long-term efficacy and safety of ropeginterferon alfa-2b in patients with polycythemia vera\u2014final phase I\/II Peginvera study results. Blood. 2018;132(Supplement 1):3030.","journal-title":"Blood"},{"key":"3341_CR30","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","volume":"7","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7:e196-208.","journal-title":"Lancet Haematol"},{"key":"3341_CR31","unstructured":"Gisslinger H, Grohmann\u2010Izay B, Georgiev P, Skotnicki A, Gercheva\u2010Kyuchukova L, Egyed M, et al. Final results from PEN-PV study, a single-arm phase 3 trial assessing the ease of self-administrating ropeginterferon alfa-2b using a pre-filled PEN in polycythemia vera patients. Haematologica. 2017; 102(s2):816\u20137 (abstract PB2053)."},{"key":"3341_CR32","unstructured":"European Medicines Agency. Besremi (ropeginterferon alfa-2b). Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/besremi. Accessed 15 December 2021."},{"key":"3341_CR33","unstructured":"PharmaEssentia. PharmaEssentia receives regulatory approval in South Korea for Besremi (ropeginterferon alfa-2b) to treat polycythemia vera. 2021. Available at: https:\/\/us.pharmaessentia.com\/wp-content\/uploads\/2021\/10\/S-Korea-Approval-14-Oct.pdf. Accessed 15 December 2021."},{"key":"3341_CR34","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/jgh3.12613","volume":"5","author":"HH Lin","year":"2021","unstructured":"Lin HH, Hsu SJ, Lu SN, Chuang WL, Hsu CW, Chien RN, et al. Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy. JGH Open. 2021;5:929\u201340.","journal-title":"JGH Open"},{"key":"3341_CR35","unstructured":"United States Food & Drug Administration. FDA news release: FDA approves treatment for rare blood disease. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-treatment-rare-blood-disease. Accessed 15 December 2021."},{"key":"3341_CR36","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40261-021-01026-5","volume":"41","author":"N Miyachi","year":"2021","unstructured":"Miyachi N, Zagrijtschuk O, Kang L, Yonezu K, Qin A. Pharmacokinetics and pharmacodynamics of ropeginterferon alfa-2b in healthy Japanese and Caucasian subjects after single subcutaneous administration. Clin Drug Investig. 2021;41:391\u2013404.","journal-title":"Clin Drug Investig"},{"key":"3341_CR37","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/sj.leu.2404955","volume":"22","author":"A Tefferi","year":"2008","unstructured":"Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22:14\u201322.","journal-title":"Leukemia"},{"key":"3341_CR38","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"3341_CR39","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1111\/j.1365-2141.2009.08019.x","volume":"148","author":"G Barosi","year":"2010","unstructured":"Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch H, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol. 2010;148:961\u20133.","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"3341_CR40","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1182\/blood-2020-142504","volume":"136","author":"K Kirito","year":"2020","unstructured":"Kirito K, Shimoda K, Takenaka K, Qin A, Zagrijtschuk O, Sato T, et al. The rationale, design, and baseline characteristics of a phase 2 study to evaluate the safety and efficacy of ropeginterferon alfa-2b (P1101) in Japanese patients with polycythemia vera for whom the current standard of care is difficult to apply. Blood. 2020;136(Supplement 1):24\u20135.","journal-title":"Blood"},{"key":"3341_CR41","doi-asserted-by":"publisher","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","volume":"113","author":"G Barosi","year":"2009","unstructured":"Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009;113:4829\u201333.","journal-title":"Blood"},{"key":"3341_CR42","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","volume":"121","author":"G Barosi","year":"2013","unstructured":"Barosi G, Mesa R, Finazzi G, Harrison C, Kiladjian JJ, Lengfelder E, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013;121:4778\u201381.","journal-title":"Blood"},{"issue":"Supplement 1","key":"3341_CR43","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1182\/blood-2018-99-118715","volume":"132","author":"H Gisslinger","year":"2018","unstructured":"Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Evidence for superior efficacy and disease modification after three years of prospective randomized controlled treatment of polycythemia vera patients with ropeginterferon alfa-2b vs. HU\/BAT.  Blood. 2018;132(Supplement 1):579.","journal-title":"Blood"},{"key":"3341_CR44","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","volume":"112","author":"JJ Kiladjian","year":"2008","unstructured":"Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112:3065\u201372.","journal-title":"Blood"},{"key":"3341_CR45","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1182\/blood-2012-07-442012","volume":"122","author":"A Quint\u00e1s-Cardama","year":"2013","unstructured":"Quint\u00e1s-Cardama A, Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie AL, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon \u03b1-2a. Blood. 2013;122:893\u2013901.","journal-title":"Blood"},{"key":"3341_CR46","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s12185-014-1721-9","volume":"101","author":"S Shirane","year":"2015","unstructured":"Shirane S, Araki M, Morishita S, Edahiro Y, Sunami Y, Hironaka Y, et al. Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia. Int J Hematol. 2015;101:148\u201353.","journal-title":"Int J Hematol"},{"key":"3341_CR47","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1155\/2009\/651952","volume":"23","author":"N Mistry","year":"2009","unstructured":"Mistry N, Shapero J, Crawford RI. A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin. Can J Gastroenterol. 2009;23:677\u201383.","journal-title":"Can J Gastroenterol"},{"key":"3341_CR48","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1179\/joc.2005.17.2.212","volume":"17","author":"G Taliani","year":"2005","unstructured":"Taliani G, Biliotti E, Capanni M, Tozzi A, Bresci S, Pimpinelli N. Reversible alopecia universalis during treatment with PEG-interferon and ribavirin for chronic hepatitis C. J Chemother. 2005;17:212\u20134.","journal-title":"J Chemother"},{"key":"3341_CR49","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s12185-018-2421-7","volume":"107","author":"K Misawa","year":"2018","unstructured":"Misawa K, Yasuda H, Araki M, Ochiai T, Morishita S, Shirane S, et al. Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms. Int J Hematol. 2018;107:673\u201380.","journal-title":"Int J Hematol"}],"updated-by":[{"DOI":"10.1007\/s12185-022-03440-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T00:00:00Z","timestamp":1661558400000}}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03341-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03341-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03341-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T12:19:32Z","timestamp":1661602772000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03341-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,16]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["3341"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03341-9","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,16]]},"assertion":[{"value":"9 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2022","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12185-022-03440-7","URL":"https:\/\/doi.org\/10.1007\/s12185-022-03440-7","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YE reports grants or contracts from PharmaEssentia Japan K.K. and Meiji Seika Pharma Co., Ltd; and honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from PharmaEssentia Japan K.K., Novartis Pharma K.K. and Takeda Pharmaceutical Co., Ltd.; and participation on a data safety monitoring board or advisory board from PharmaEssentia Japan K.K. and Novartis Pharma K.K. KO has no conflicts of interest to declare. AG reports research funding from Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Chugai Pharmaceutical Co., Ltd., MSD K.K., Otsuka Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Bayer Yakuhin, Ltd., Daiichi Sankyo Co., Ltd., and Nihon Pharmaceutical Co., Ltd; honoraria from Novartis Pharma K.K., Alexion Pharmaceuticals, Inc., Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Chugai Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Nihon Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Janssen Pharmaceutical K.K., Pfizer Japan Inc., and Sanofi K.K.; consulting fees from PharmaEssentia Japan K.K., Chugai Pharmaceutical, and Alexion Pharmaceuticals, Inc.; and participation on a data safety monitoring board or advisory board from PharmaEssentia Japan K.K., Chugai Pharmaceutical, and Alexion Pharmaceuticals, Inc. KT reports research funding and consulting fees from Astellas Pharma Inc., PharmaEssentia Japan K.K., Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Otsuka Pharmaceutical Co., Ltd.; and honoraria from Novartis Pharma K.K., Kyowa Kirin Co., Ltd., MSD K.K. Ltd. and Alexion Pharmaceuticals, Inc. HS reports honoraria from Takeda Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Novartis Pharma K.K., Celgene K.K., Janssen Pharmaceutical K.K., Chugai Pharmaceutical Co., Ltd., Sanofi K.K., AstraZeneca K.K., AbbVie G.K., SymBio Pharmaceuticals Ltd., Eisai Co., Ltd., and Kyowa Kirin Co., Ltd.; and research funding from PharmaEssentia Japan K.K., Janssen Pharmaceutical K.K., Ono Pharmaceutical Co., Ltd., Celgene K.K., Novartis Pharma K.K., Sanofi K.K., AstraZeneca K.K., AbbVie G.K., Eisai Co., Ltd., HUYA Bioscience International, LLC., and Chugai Pharmaceutical Co., Ltd.; and scholarship endowment from Astellas Pharma Inc., Teijin Pharma Ltd., Shionogi & Co., Ltd., Eisai Co., Ltd., Sanofi K.K., Taiho Pharmaceutical Co., Ltd., and Nippon Shinyaku Co., Ltd. TaS reports honoraria from Ono Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Chugai Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Eisai Co., Ltd., SymBio Pharmaceuticals Ltd., Takeda Pharmaceutical Co., Ltd., Celgene K.K., Bristol-Myers Squibb K.K., Kyowa Kirin Co., Ltd., and Pfizer Japan Inc. KU reports research funding from Astellas Pharma Inc., AbbVie GK, Apellis Pharmaceuticals, Inc., SymBio Pharmaceuticals Ltd., Daiichi Sankyo Co., Ltd., Novartis Pharma K.K., Janssen Pharmaceutical K.K., Otsuka Pharmaceutical Co., Ltd., Amgen-Astellas Biopharma K.K., Takeda Pharmaceutical Co., Ltd., Nippon-Shinyaku Co., Ltd., Bristol Myers Squibb K.K., Amgen K.K., Alexion Pharmaceuticals, Inc., Incyte Biosciences Japan G.K., Ono Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Celgene K.K., Sumitomo Dainippon Pharma Co., Ltd., Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., Mundipharma K.K., Yakult Honsha Co., Ltd., MSD K.K., Gilead Sciences, Inc., and Nippon Boehringer Ingelheim Co., Ltd.; and honoraria from Novartis Pharma K.K., Bristol Myers Squibb K.K., Sanofi K.K., Pfizer Japan Inc., AbbVie GK, Takeda Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Astellas Pharma Inc., Alexion Pharmaceuticals, Inc., Eisai Co., Ltd., MSD K.K., Otsuka Pharmaceutical Co., Ltd., Celgene K.K., Daiichi Sankyo Co., Ltd., Nippon-Shinyaku Co., Ltd., PharmaEssentia Japan K.K., Yakult Honsha Co., Ltd., SymBio Pharmaceuticals Ltd., and Chugai Pharmaceutical Co., Ltd. KS is a consultant for Sierra and reports research funding from PharmaEssentia Japan K.K., Chugai Pharmaceutical Co., Ltd., AbbVie GK, Kyowa Kirin Co., Ltd., Daiichi Sankyo Co., Ltd., Shionogi & Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Eisai Co., Ltd., Nippon Kayaku Co., Ltd., Takeda Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., and Taisho Pharmaceutical Co., Ltd.; honoraria from Novartis Pharma K.K. and Takeda Pharmaceutical Co., Ltd.; and is a member of an advisory committee for AbbVie GK. MI reports honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Takeda Pharmaceutical Co., Ltd. and Novartis Pharma K.K. SV is an employee of Enhanced Pharmacodynamics, LLC. OZ is an employee of PharmaEssentia Corporation USA. AQ is an employee of PharmaEssentia Corporation, Taiwan. HK, NM and ToS are employees of PharmaEssentia Japan KK. NK is a consultant for AbbVie G.K., Otsuka Pharmaceutical Co., Ltd., Celgene K.K., Japan Tobacco Inc., and PharmaEssentia Japan K.K.; and reports honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Shire Japan K.K., Novartis Pharma K.K., and Takeda Pharmaceutical Co., Ltd.; and is the Chairperson and Executive Director of PharmaEssentia Japan K.K. KK reports honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novartis Pharma K.K., Takeda Pharmaceutical Co., Ltd., PharmaEssentia Japan K.K., Sanofi K.K., and AbbVie G.K.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}